
TriSalus Life Sciences, Inc.: shareholders and insiders
Price
$2.32
November 20, 2026Market cap $142M
What Ploutos Investor adds for TriSalus Life Sciences
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 22% since Nov 10, 2026, when the 10-Q these figures come from was filed ($2.85 then, $2.22 on Nov 20, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Nov 19, 2026, from their own Form 4 filings.
Bought on the market
$3.8M
5 people
Sold on the market
$141.2K
5 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan0%
- The rest100%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $3.8M by 5 people·sold $141.2K by 5 people
- 2025: no buys, no sales
- 2026: bought $3.8M by 5 people, sold $141.2K by 5 people
- Nov 18, 2026Mary T SzelaCEO and PresidentKind
- Nov 17, 2026Mary T SzelaCEO and PresidentKind
- Nov 17, 2026Gary B. GordonDirectorKind
- Nov 16, 2026Richard MarshakChief Commercial OfficerKind
- Nov 12, 2026Mats WahlstromDirectorKind
- Oct 5, 2026Bryan F. CoxChief of ResearchKind
- Oct 5, 2026Richard MarshakChief Commercial OfficerKind
- Oct 5, 2026Jennifer StevensChief Regulatory OfficerKind
- Oct 5, 2026Mary T SzelaCEO and PresidentKind
- Jul 1, 2026David PatienceChief Financial OfficerKind
- Jun 30, 2026Mary T SzelaCEO and PresidentKind
- Jun 30, 2026Richard MarshakChief Commercial OfficerKind
- Jun 29, 2026Richard Henry MarshallChief Medical OfficerKind
- May 15, 2026Gary B. GordonKind
- May 15, 2026David PatienceChief Financial OfficerKind
- May 15, 2026Mary T SzelaCEO and PresidentKind
- May 15, 2026Michael P StanskyKind
- May 15, 2026Michael P StanskyKind
- May 15, 2026Mats WahlstromKind
- May 15, 2026Richard MarshakChief Commercial OfficerKind
- Mar 17, 2026Mary T SzelaCEO and PresidentKind
- Mar 16, 2026Jennifer StevensChief Regulatory OfficerKind
- Mar 16, 2026Richard MarshakChief Commercial OfficerKind
- Mar 16, 2026Bryan F. CoxChief of ResearchKind
- Mar 16, 2026Jodi DevlinChief of Clinical OperationsKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2026 | Mary T SzelaCEO and President | 34.3K | $2.59 | $88.9K | Form 4 | |
| Nov 17, 2026 | Mary T SzelaCEO and President | 30.9K | $2.31 | $71.3K | Form 4 | |
| Nov 17, 2026 | Gary B. GordonDirector | 10.0K | $2.20 | $22.0K | Form 4 | |
| Nov 16, 2026 | Richard MarshakChief Commercial Officer | 544 | $2.43 | $1.3K | Form 4 | |
| Nov 12, 2026 | Mats WahlstromDirector | 50.0K | $2.24 | $112.0K | Form 4 | |
| Oct 5, 2026 | Bryan F. CoxChief of Research | 296 | $4.39 | $1.3K | Form 4 | |
| Oct 5, 2026 | Richard MarshakChief Commercial Officer | 325 | $4.39 | $1.4K | Form 4 | |
| Oct 5, 2026 | Jennifer StevensChief Regulatory Officer | 316 | $4.39 | $1.4K | Form 4 | |
| Oct 5, 2026 | Mary T SzelaCEO and President | 2,693 | $4.38 | $11.8K | Form 4 | |
| Jul 1, 2026 | David PatienceChief Financial Officer | 14.7K | $4.46 | $65.3K | Form 4 | |
| Jun 30, 2026 | Mary T SzelaCEO and President | 3,990 | $3.87 | $15.4K | Form 4 | |
| Jun 30, 2026 | Richard MarshakChief Commercial Officer | 561 | $3.87 | $2.2K | Form 4 | |
| Jun 29, 2026 | Richard Henry MarshallChief Medical Officer | 60.0K | – | – | Form 4 | |
| May 15, 2026 | Gary B. Gordon | 10.0K | $2.46 | $24.6K | Form 4 | |
| May 15, 2026 | David PatienceChief Financial Officer | 7,100 | $2.43 | $17.3K | Form 4 | |
| May 15, 2026 | Mary T SzelaCEO and President | 39.7K | $2.59 | $102.8K | Form 4 | |
| May 15, 2026 | Michael P Stansky | 200.0K | $2.50 | $500.0K | Form 4 | |
| May 15, 2026 | Michael P Stansky | 410.0K | $2.50 | $1.0M | Form 4 | |
| May 15, 2026 | Mats Wahlstrom | 60.0K | $2.53 | $151.8K | Form 4 | |
| May 15, 2026 | Richard MarshakChief Commercial Officer | 543 | $2.67 | $1.4K | Form 4 | |
| Mar 17, 2026 | Mary T SzelaCEO and President | 15.9K | $3.85 | $61.4K | Form 4 | |
| Mar 16, 2026 | Jennifer StevensChief Regulatory Officer | 774 | $4.12 | $3.2K | Form 4 | |
| Mar 16, 2026 | Richard MarshakChief Commercial Officer | 419 | $4.12 | $1.7K | Form 4 | |
| Mar 16, 2026 | Bryan F. CoxChief of Research | 579 | $4.12 | $2.4K | Form 4 | |
| Mar 16, 2026 | Jodi DevlinChief of Clinical Operations | 273 | $4.12 | $1.1K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 29, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by TLSI's officers and directors from 2024 up to November 20, 2025, 2 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Frankenius Equity ABwith 1 more personShare of class14.0%
- First Light Asset Management, LLCwith 1 more personShare of class10.7%
- Mats Wahlstromwith 2 more personsShare of class6.00%
- Utmost Group PLCShare of class5.71%
- James J. PallottaShare of class5.20%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Frankenius Equity ABwith 1 more person | 14.0% | 6.99M | Aug 4, 20253 filings since Dec 19, 2024 | 13D/A | |
| First Light Asset Management, LLCwith 1 more person | 10.7% | 6.60M | Jul 7, 20262 filings since May 15, 2026 | 13G/A | |
| Mats Wahlstromwith 2 more persons | 6.00% | 2.99M | Aug 1, 20252 filings since Dec 19, 2024 | 13D/A | |
| Utmost Group PLC | 5.71% | 3.50M | May 12, 20263 filings since Aug 18, 2025 | 13G | |
| James J. Pallotta | 5.20% | 3.19M | May 20, 2026 | 13G/A |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Frankenius Equity AB14.0%From the filing of Aug 4, 2025
Item 4 of the Statement is hereby amended and supplemented as follows: On June 23, 2025, the Issuer filed a Form S-4 announcing the Exchange Offer (the "Offer") of Common Stock in exchange for the shares of the Issuer's Preferred Stock, which equated to an exchange ratio of 3.3 shares of Common Stock for each share of Preferred Stock exchanged pursuant to the Offer. The Offer expired at one minute after 11:59 P.M. Eastern Daylight Time on July 23, 2025 and the conversions were completed on July 31, 2025. Frankenius Equity AB accepted the Exchange and was issued 759,000 shares of Common Stock in exchange for their 230,000 shares of Preferred Stock.
From the filing of Aug 4, 2025Mats Wahlstrom6.0%From the filing of Aug 1, 2025
Item 4 of the Statement is hereby amended and supplemented as follows: On June 23, 2025, the Issuer filed a Form S-4 announcing the Exchange Offer (the "Offer") of Common Stock in exchange for the shares of the Issuer's Preferred Stock, which equated to an exchange ratio of 3.3 shares of Common Stock for each share of Preferred Stock exchanged pursuant to the Offer. The Offer expired at one minute after 11:59 P.M. Eastern Daylight Time on July 23, 2025 and the conversions were completed on July 31, 2025. Leonard Capital, LLC. accepted the Exchange and was issued 165,000 shares of Common Stock in exchange for their 50,000 shares of Preferred Stock.
From the filing of Aug 1, 2025
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Nantahala Capital Management, LLC4.09%Nov 14, 202513G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter
- D.E. ShawIn the quarter
- AQR CapitalIn the quarter-3.2%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | 36.1K | $200.0K | 0.00% | |
| D.E. Shaw | 12.5K | $100.0K | 0.00% | |
| AQR Capital | 114.2K | -3.2% | $500.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 5.62% of its shares outstanding were held short, +2.9% since the report before.
- Shares held short
- 3.44M
- 5.62%
- Since the report before3.35M on Sep 30, 2026
- +2.9%
- 20.1
- 171.3K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 99%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 5,720
- Nov 15, 2023: Shares held short 3,223
- Nov 30, 2023: Shares held short 8,580
- Dec 15, 2023: Shares held short 66.3K
- Dec 29, 2023: Shares held short 180.6K
- Jan 12, 2024: Shares held short 250.6K
- Jan 31, 2024: Shares held short 267.8K
- Feb 15, 2024: Shares held short 252.9K
- Feb 29, 2024: Shares held short 255.4K
- Mar 15, 2024: Shares held short 254.9K
- Mar 28, 2024: Shares held short 287.4K
- Apr 15, 2024: Shares held short 276.3K
- Apr 30, 2024: Shares held short 169.6K
- May 15, 2024: Shares held short 172.1K
- May 31, 2024: Shares held short 413.4K
- Jun 14, 2024: Shares held short 421.9K
- Jun 28, 2024: Shares held short 453.5K
- Jul 15, 2024: Shares held short 52.3K
- Jul 31, 2024: Shares held short 42.9K
- Aug 15, 2024: Shares held short 41.0K
- Aug 30, 2024: Shares held short 32.9K
- Sep 13, 2024: Shares held short 31.5K
- Sep 30, 2024: Shares held short 51.2K
- Oct 15, 2024: Shares held short 62.1K
- Oct 31, 2024: Shares held short 58.4K
- Nov 15, 2024: Shares held short 31.8K
- Nov 29, 2024: Shares held short 46.9K
- Dec 13, 2024: Shares held short 57.6K
- Dec 31, 2024: Shares held short 83.8K
- Jan 15, 2025: Shares held short 83.0K
- Jan 31, 2025: Shares held short 73.0K
- Feb 14, 2025: Shares held short 128.0K
- Feb 28, 2025: Shares held short 136.1K
- Mar 14, 2025: Shares held short 124.0K
- Mar 31, 2025: Shares held short 123.0K
- Apr 15, 2025: Shares held short 26.4K
- Apr 30, 2025: Shares held short 35.6K
- May 15, 2025: Shares held short 109.0K
- May 30, 2025: Shares held short 32.7K
- Jun 13, 2025: Shares held short 119.7K
- Jun 30, 2025: Shares held short 550.4K
- Jul 15, 2025: Shares held short 605.3K
- Jul 31, 2025: Shares held short 582.9K
- Aug 15, 2025: Shares held short 552.8K
- Aug 29, 2025: Shares held short 457.1K
- Sep 15, 2025: Shares held short 515.4K
- Sep 30, 2025: Shares held short 918.5K
- Oct 15, 2025: Shares held short 730.1K
- Oct 31, 2025: Shares held short 642.6K
- Nov 14, 2025: Shares held short 637.3K
- Nov 28, 2025: Shares held short 754.6K
- Dec 15, 2025: Shares held short 794.5K
- Dec 31, 2025: Shares held short 1.28M
- Jan 15, 2026: Shares held short 1.26M
- Jan 30, 2026: Shares held short 1.14M
- Feb 13, 2026: Shares held short 1.16M
- Feb 27, 2026: Shares held short 986.7K
- Mar 13, 2026: Shares held short 1.08M
- Mar 31, 2026: Shares held short 1.20M
- Apr 15, 2026: Shares held short 1.32M
- Apr 30, 2026: Shares held short 1.44M
- May 15, 2026: Shares held short 1.69M
- May 29, 2026: Shares held short 2.10M
- Jun 15, 2026: Shares held short 2.19M
- Jun 30, 2026: Shares held short 3.08M
- Jul 15, 2026: Shares held short 3.56M
- Jul 31, 2026: Shares held short 3.77M
- Aug 14, 2026: Shares held short 3.79M
- Aug 31, 2026: Shares held short 3.69M
- Sep 15, 2026: Shares held short 3.35M
- Sep 30, 2026: Shares held short 3.35M
- Oct 15, 2026: Shares held short 3.44M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading53.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 53.2% of the shares in the reported trades were short sales, against 56.8% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 53.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 56.8%
- Change
- -3.6 pts
- Short sales a dayon average, of 218.7K shares
- 116.2K
- More than atof 3,674 US-listed companies, same days
- 60%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 54.2%
- Oct 15, 2026: Short sales 26%
- Oct 16, 2026: Short sales 86.3%
- Oct 19, 2026: Short sales 59.3%
- Oct 20, 2026: Short sales 51.3%
- Oct 21, 2026: Short sales 37.7%
- Oct 22, 2026: Short sales 47.6%
- Oct 23, 2026: Short sales 59.7%
- Oct 26, 2026: Short sales 62.1%
- Oct 27, 2026: Short sales 24.2%
- Oct 28, 2026: Short sales 66.8%
- Oct 29, 2026: Short sales 58.8%
- Oct 30, 2026: Short sales 64.6%
- Nov 2, 2026: Short sales 68.7%
- Nov 3, 2026: Short sales 74.2%
- Nov 4, 2026: Short sales 59.8%
- Nov 5, 2026: Short sales 58.9%
- Nov 6, 2026: Short sales 37.4%
- Nov 9, 2026: Short sales 72.6%
- Nov 10, 2026: Short sales 33.3%
- Nov 11, 2026: Short sales 58.7%
- Nov 12, 2026: Short sales 59.6%
- Nov 13, 2026: Short sales 78.2%
- Nov 16, 2026: Short sales 65.4%
- Nov 17, 2026: Short sales 49.5%
- Nov 18, 2026: Short sales 72.7%
- Nov 19, 2026: Short sales 59.7%
- Nov 20, 2026: Short sales 58%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Equity AB FrankeniusTenPercentOwnerDirectly6.23M
- Mats WahlstromDirectorDirectly3.01M
- Michael P StanskyDirectorDirectly1.24M
- Mary T SzelaCEO and PresidentDirectly1.14M
- David PatienceChief Financial OfficerDirectly261.1K
- George Kelly MartinDirectorDirectly–
- Arjun JJ DesaiDirectorDirectly247.1K
- Sean MurphyChief Manuf, Strategy&Bus Dev.Directly–
- Bryan F. CoxChief of ResearchDirectly162.8K
- Richard MarshakChief Commercial OfficerDirectly127.5K
- Jennifer StevensChief Regulatory OfficerDirectly123.8K
- Jodi DevlinChief of Clinical OperationsDirectly97.4K
- Richard Henry MarshallChief Medical OfficerDirectly90.0K
- Gary B. GordonDirectorDirectly82.5K
- William ValleDirectorDirectly30.5K
- James Emmett YoungChief Financial OfficerDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Equity AB FrankeniusTenPercentOwner | 6.23M | – | Dec 17, 2024 | Form 4 |
| Mats WahlstromDirector | 3.01M | – | Nov 12, 2026 | Form 4 |
| Michael P StanskyDirector | 1.24M | 399.7K | May 15, 2026 | Form 4 |
| Mary T SzelaCEO and President | 1.14M | – | Nov 18, 2026 | Form 4 |
| David PatienceChief Financial Officer | 261.1K | – | Jul 1, 2026 | Form 4 |
| George Kelly MartinDirector | – | 247.2K | Aug 28, 2024 | Form 4 |
| Arjun JJ DesaiDirector | 247.1K | – | Dec 10, 2024 | Form 4 |
| Sean MurphyChief Manuf, Strategy&Bus Dev. | – | 197.7K | Jan 28, 2025 | Form 4 |
| Bryan F. CoxChief of Research | 162.8K | – | Oct 5, 2026 | Form 4 |
| Richard MarshakChief Commercial Officer | 127.5K | – | Nov 16, 2026 | Form 4 |
| Jennifer StevensChief Regulatory Officer | 123.8K | – | Oct 5, 2026 | Form 4 |
| Jodi DevlinChief of Clinical Operations | 97.4K | – | Mar 16, 2026 | Form 4 |
| Richard Henry MarshallChief Medical Officer | 90.0K | – | Jun 29, 2026 | Form 4 |
| Gary B. GordonDirector | 82.5K | – | Nov 17, 2026 | Form 4 |
| William ValleDirector | 30.5K | – | Feb 23, 2026 | Form 4 |
| James Emmett YoungChief Financial Officer | – | 30.0K | Feb 5, 2025 | Form 4 |
A lower bound: it counts only the 16 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.05%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
6 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 56
- Q4 2025: Managers 64
- Q1 2026: Managers 84
- Q2 2026: Managers 79
Institutional investors by quarter
The fund managers holding TLSI, quarter by quarter, from Q3 2023 to Q2 2025, 8 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 79 managers held 22.76M shares, worth $104M. During the quarter 12 opened a position, 17 closed one, 43 added and 10 trimmed.
The largest holders, Q2 2026
- First Light Asset ManagementIn the quarter+29%
- BlackRockIn the quarter+77%
- Nantahala Capital ManagementIn the quarter-3.4%
- Vanguard Capital ManagementIn the quarter+28%
- Cerity PartnersIn the quarter+104%
- Geode Capital ManagementIn the quarter+53%
- Gilder Gagnon HoweIn the quarter-4.3%
- State StreetIn the quarter+86%
- White Pine CapitalIn the quarter+51%
- Thompson Siegel & WalmsleyIn the quarter-8.1%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| First Light Asset Management | 6.55M | +29% | $30M |
| BlackRock | 2.66M | +77% | $12M |
| Nantahala Capital Management | 2.00M | -3.4% | $9.1M |
| Vanguard Capital Management | 1.73M | +28% | $7.9M |
| Cerity Partners | 1.60M | +104% | $7.3M |
| Geode Capital Management | 1.19M | +53% | $5.4M |
| Gilder Gagnon Howe | 850.1K | -4.3% | $3.9M |
| State Street | 611.0K | +86% | $2.8M |
| White Pine Capital | 547.6K | +51% | $2.5M |
| Thompson Siegel & Walmsley | 536.5K | -8.1% | $2.4M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do TriSalus Life Sciences's filings show?
Who buys and sells is one part of TriSalus Life Sciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have TLSI's insiders bought or sold?
From Jun 29, 2026 to Nov 19, 2026 TriSalus Life Sciences's insiders bought $294.2K and sold $5.4K of shares on the market. 0% of the sales were under set 10b5-1 plans.
Which well-known managers hold TLSI?
3 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $500.0K.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.